Prevalence of Fabry's Disease in a Population of Patients With Chronic Pains (DOUFAB)
Primary Purpose
Pain, Fabry's Disease
Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Blood sampling for biological and genetic analysis
Sponsored by
About this trial
This is an interventional diagnostic trial for Pain focused on measuring chronic pains, unknown aetiology
Eligibility Criteria
Inclusion Criteria:
- patients of both sex
- aged from 6 to 65
- with chronic pains of unknown aetiology including:
- acroparesthesias
- and/or pain crises evolving more than 3 months
- continued neuropathic evolving more than 3 months
- and/or multiple pains evolving more than 3 months
- and/or recurrent abdominal crises of pain who come for a clinical visit in the Centre Douleurs Chroniques in the CHU of Bordeaux.
Exclusion Criteria:
- chronic pain of known cause
Sites / Locations
- Centre Douleurs Chroniques, Hopital Pellegrin
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Diagnosis of Fabry disease
Arm Description
Outcomes
Primary Outcome Measures
Diagnosis of Fabry disease in one patient suffering from chronic pains
Secondary Outcome Measures
Full Information
NCT ID
NCT01178164
First Posted
August 4, 2010
Last Updated
April 3, 2013
Sponsor
University Hospital, Bordeaux
1. Study Identification
Unique Protocol Identification Number
NCT01178164
Brief Title
Prevalence of Fabry's Disease in a Population of Patients With Chronic Pains
Acronym
DOUFAB
Official Title
Prevalence of Fabry's Disease in a Population of Patients With Chronic Pains
Study Type
Interventional
2. Study Status
Record Verification Date
April 2013
Overall Recruitment Status
Completed
Study Start Date
September 2010 (undefined)
Primary Completion Date
September 2012 (Actual)
Study Completion Date
September 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Bordeaux
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Fabry disease (FD) is a rare X-linked multisytemic lysosomal disorder caused by alpha-galactosidase deficiency. Globotriaosylcéramide (Gb3) deposits are observed in almost all tissues examined. Signs of the disease appear earlier and are more severe in affected males than in females. Myocardiopathy, renal failure and neurological signs including chronic pain and peripheral neuropathies are the most frequent signs. The availability of two enzymatic replacement therapies now provides a specific and effective treatment for patients. The prevalence of FD is estimated between 1/40,000 and 1/117,000. The frequency of Fabry disease has previously been estimated in several series of patients presenting one single sign, ie renal failure, hypertrophic myocardiopathy and early onset stroke. However, no data are available about the prevalence of FD in populations of patients suffering from chronic pains of unknown origin.
The diagnosis of FD will be performed by standard procedures following international recommendations. These require the search for a deficiency of alphagalactosidase A activity on leucocytes in males and genetic analysis of the GLA gene in females (Lidove et al. 2007).
The patients in whom the diagnosis of FD is established during this study, will be call in for an additional visit in the Investigating Centre in order to confirm the diagnosis and propose suitable assessment and care.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pain, Fabry's Disease
Keywords
chronic pains, unknown aetiology
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
137 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Diagnosis of Fabry disease
Arm Type
Experimental
Intervention Type
Genetic
Intervention Name(s)
Blood sampling for biological and genetic analysis
Intervention Description
Clinical examination
Blood sampling for biochemical enzymatic measures of alphagalactosidase A activity in males, and genetic analysis using direct sequencing of GLA in females.
Primary Outcome Measure Information:
Title
Diagnosis of Fabry disease in one patient suffering from chronic pains
Time Frame
1 year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
6 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
patients of both sex
aged from 6 to 65
with chronic pains of unknown aetiology including:
acroparesthesias
and/or pain crises evolving more than 3 months
continued neuropathic evolving more than 3 months
and/or multiple pains evolving more than 3 months
and/or recurrent abdominal crises of pain who come for a clinical visit in the Centre Douleurs Chroniques in the CHU of Bordeaux.
Exclusion Criteria:
chronic pain of known cause
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Virginie DOUSSET, MD
Organizational Affiliation
University Hospital, Bordeaux
Official's Role
Principal Investigator
Facility Information:
Facility Name
Centre Douleurs Chroniques, Hopital Pellegrin
City
Bordeaux Cedex
ZIP/Postal Code
33076
Country
France
12. IPD Sharing Statement
Learn more about this trial
Prevalence of Fabry's Disease in a Population of Patients With Chronic Pains
We'll reach out to this number within 24 hrs